• vcard
312.873.3655
  • Education
    • J.D., Northwestern University School of Law, 2005
    • Ph.D., Baylor College of Medicine, 2000
    • B.S., summa cum laude, University of Houston, 1995, Biochemical Sciences
  • Bar Jurisdictions
    • Illinois, 2005
    • Admitted to practice before the United States Patent and Trademark Office, 2017
Chris Cabral’s background in science allows him to help clients develop effective strategies for protecting their intellectual property. He counsels clients in all aspects of patent prosecution and patent counseling, including opinion work specific to freedom to operate, invalidity, non-infringement, patentability, and industry landscape analyses. Chris is well versed in all phases of domestic and foreign patent prosecution, and his patent procurement experience involves preparing and prosecuting domestic and foreign patent applications for clients in the life science and chemical areas, with particular emphasis on the biotechnology, pharmaceutical, diagnostics, and small molecule arenas. Chris has also represented client’s patents by post grant proceedings and in the defense of their patents.
  • Successfully defended an inventorship challenge filed by a third party against a patent owned by a small molecule pharmaceutical company client at the district court and on appeal to the Federal Circuit
  • Preparing, prosecuting and managing complex United States and international patent portfolios covering selective progesterone receptor modifiers and selective estrogen receptor modifiers
  • Preparing, prosecuting and managing complex United States and international patent portfolios covering genetically modified microorganisms
  • Conducted non-infringement and invalidity opinions for an international pharmaceutical manufacturer
  • Preparing, prosecuting and managing complex United States and international patent portfolios covering medical diagnostic methods for several molecular diagnostic companies
  • Counseled several biotechnology companies and maintained their United States and international patent portfolios directed to oncolytic viruses